Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance

References

• Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE. Constitutive Type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012; 36:166 - 74; http://dx.doi.org/10.1016/j.immuni.2012.01.011; PMID: 22365663
   PubMed Web of Science ®Google Scholar
• Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T, et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000; 13:643 - 55; http://dx.doi.org/10.1016/S1074-7613(00)00064-9; PMID: 11114377
   PubMed Web of Science ®Google Scholar
• Honda K, Mizutani T, Taniguchi T. Negative regulation of IFN-alpha/beta signaling by IFN regulatory factor 2 for homeostatic development of dendritic cells. Proc Natl Acad Sci U S A 2004; 101:2416 - 21; http://dx.doi.org/10.1073/pnas.0307336101; PMID: 14983024
   PubMed Web of Science ®Google Scholar
• Mizutani T, Tsuji K, Ebihara Y, Taki S, Ohba Y, Taniguchi T, et al. Homeostatic erythropoiesis by the transcription factor IRF2 through attenuation of Type I interferon signaling. Exp Hematol 2008; 36:255 - 64; http://dx.doi.org/10.1016/j.exphem.2007.11.004; PMID: 18207304
   PubMed Web of Science ®Google Scholar
• Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from Type I interferon-dependent exhaustion. Nat Med 2009; 15:696 - 700; http://dx.doi.org/10.1038/nm.1973; PMID: 19483695
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89:884 - 93; http://dx.doi.org/10.1016/j.biochi.2007.04.006; PMID: 17532550
   PubMed Web of Science ®Google Scholar
• Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010; 43:204 - 9; http://dx.doi.org/10.3109/08916930903510880; PMID: 20187707
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565 - 70; http://dx.doi.org/10.1126/science.1203486; PMID: 21436444
   PubMed Web of Science ®Google Scholar
• Smyth MJ. Type I interferon and cancer immunoediting. Nat Immunol 2005; 6:646 - 8; http://dx.doi.org/10.1038/ni0705-646; PMID: 15970935
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for Type I interferons in cancer immunoediting. Nat Immunol 2005; 6:722 - 9; http://dx.doi.org/10.1038/ni1213; PMID: 15951814
   PubMed Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836 - 48; http://dx.doi.org/10.1038/nri1961; PMID: 17063185
   PubMed Web of Science ®Google Scholar
• Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol 2011; 11:645 - 57; http://dx.doi.org/10.1038/nri3044; PMID: 21869816
   PubMed Web of Science ®Google Scholar
• Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007; 7:703 - 14; http://dx.doi.org/10.1038/nri2154; PMID: 17717540
   PubMed Web of Science ®Google Scholar
• Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007; 178:7540 - 9; PMID: 17548588
   PubMed Web of Science ®Google Scholar
• Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004; 114:1650 - 8; PMID: 15578097
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341:164 - 72; http://dx.doi.org/10.1056/NEJM199907153410306; PMID: 10403855
   PubMed Web of Science ®Google Scholar
• Specchia G, Mininni D, Guerrasio A, Palumbo G, Pastore D, Liso V. Ph positive acute lymphoblastic leukemia in adults: molecular and clinical studies. Leuk Lymphoma 1995; 18:Suppl 1 37 - 42; http://dx.doi.org/10.3109/10428199509075301; PMID: 7496353
   PubMed Web of Science ®Google Scholar
• Witte ON. Functions of the abl oncogene. Cancer Surv 1986; 5:183 - 97; PMID: 3465440
   PubMedGoogle Scholar
• Rosenberg N, Witte ON. The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res 1988; 35:39 - 81; http://dx.doi.org/10.1016/S0065-3527(08)60708-3; PMID: 2852893
   PubMed Web of Science ®Google Scholar
• Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN. Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci U S A 2003; 100:13453 - 8; http://dx.doi.org/10.1073/pnas.2230460100; PMID: 14597717
   PubMed Web of Science ®Google Scholar
• Hardy RR. B-cell commitment: deciding on the players. Curr Opin Immunol 2003; 15:158 - 65; http://dx.doi.org/10.1016/S0952-7915(03)00012-8; PMID: 12633665
   PubMed Web of Science ®Google Scholar
• Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol 2001; 19:595 - 621; http://dx.doi.org/10.1146/annurev.immunol.19.1.595; PMID: 11244048
   PubMed Web of Science ®Google Scholar
• Hardy RR, Li YS, Allman D, Asano M, Gui M, Hayakawa K. B-cell commitment, development and selection. Immunol Rev 2000; 175:23 - 32; http://dx.doi.org/10.1111/j.1600-065X.2000.imr017517.x; PMID: 10933588
   PubMed Web of Science ®Google Scholar
• Lienenklaus S, Cornitescu M, Zietara N, Łyszkiewicz M, Gekara N, Jabłónska J, et al. Novel reporter mouse reveals constitutive and inflammatory expression of IFN-beta in vivo. J Immunol 2009; 183:3229 - 36; http://dx.doi.org/10.4049/jimmunol.0804277; PMID: 19667093
   PubMed Web of Science ®Google Scholar
• Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006; 10:77 - 87; http://dx.doi.org/10.1016/j.ccr.2006.05.025; PMID: 16843267
   PubMed Web of Science ®Google Scholar
• Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, et al. Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood 2008; 112:4655 - 64; http://dx.doi.org/10.1182/blood-2008-02-139105; PMID: 18684865
   PubMed Web of Science ®Google Scholar
• Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 2011; 117:1565 - 73; http://dx.doi.org/10.1182/blood-2010-06-291633; PMID: 21127177
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006; 176:1517 - 24; PMID: 16424180
   PubMed Web of Science ®Google Scholar
• Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009; 113:5488 - 96; http://dx.doi.org/10.1182/blood-2008-10-187179; PMID: 19234143
   PubMed Web of Science ®Google Scholar
• Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999; 29:1390 - 6; http://dx.doi.org/10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.0.CO;2-C; PMID: 10229107
   PubMed Web of Science ®Google Scholar
• Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 2011; 117:1565 - 73; http://dx.doi.org/10.1182/blood-2010-06-291633; PMID: 21127177
   PubMed Web of Science ®Google Scholar
• Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424:516 - 23; http://dx.doi.org/10.1038/nature01850; PMID: 12872134
   PubMed Web of Science ®Google Scholar
• Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010; 120:1151 - 64; http://dx.doi.org/10.1172/JCI37223; PMID: 20237412
   PubMed Web of Science ®Google Scholar
• Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009; 119:1251 - 63; http://dx.doi.org/10.1172/JCI36022; PMID: 19349689
   PubMed Web of Science ®Google Scholar
• Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205:2965 - 73; http://dx.doi.org/10.1084/jem.20081752; PMID: 19029380
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1:119 - 26; http://dx.doi.org/10.1038/77793; PMID: 11248803
   PubMed Web of Science ®Google Scholar
• Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405 - 11; http://dx.doi.org/10.1038/7403; PMID: 10202929
   PubMed Web of Science ®Google Scholar
• van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 2003; 171:5842 - 52; PMID: 14634094
   PubMed Web of Science ®Google Scholar
• Granucci F, Zanoni I, Pavelka N, Van Dommelen SL, Andoniou CE, Belardelli F, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med 2004; 200:287 - 95; http://dx.doi.org/10.1084/jem.20040370; PMID: 15289500
   PubMed Web of Science ®Google Scholar
• Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26:503 - 17; http://dx.doi.org/10.1016/j.immuni.2007.03.006; PMID: 17398124
   PubMed Web of Science ®Google Scholar
• Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of Type I and Type II interferons in antiviral defense. Science 1994; 264:1918 - 21; http://dx.doi.org/10.1126/science.8009221; PMID: 8009221
   PubMed Web of Science ®Google Scholar
• Erlandsson L, Blumenthal R, Eloranta ML, Engel H, Alm G, Weiss S, et al. Interferon-beta is required for interferon-alpha production in mouse fibroblasts. Current biology: CB 1998; 8:223-6.
   Google Scholar
• Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28:675 - 86; http://dx.doi.org/10.1016/j.immuni.2008.03.011; PMID: 18424188
   PubMed Web of Science ®Google Scholar
• Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006; 108:3253 - 61; http://dx.doi.org/10.1182/blood-2006-06-027599; PMID: 16868248
   PubMed Web of Science ®Google Scholar
• Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995; 376:352 - 5; http://dx.doi.org/10.1038/376352a0; PMID: 7543183
   PubMed Web of Science ®Google Scholar
• Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 2000; 96:2277 - 83; PMID: 10979977
   PubMed Web of Science ®Google Scholar
• Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006; 107:4898 - 906; http://dx.doi.org/10.1182/blood-2005-09-3596; PMID: 16493008
   PubMed Web of Science ®Google Scholar
• Sexl V, Kovacic B, Piekorz R, Moriggl R, Stoiber D, Hoffmeyer A, et al. Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood 2003; 101:4937 - 43; http://dx.doi.org/10.1182/blood-2001-11-0142; PMID: 12576323
   PubMed Web of Science ®Google Scholar
• Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O, et al. The cooperating mutation or “second hit” determines the immunologic visibility toward MYC-induced murine lymphomas. Blood 2011; 118:4635 - 45; http://dx.doi.org/10.1182/blood-2010-10-313098; PMID: 21878673
   PubMed Web of Science ®Google Scholar
• Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65 - 78; http://dx.doi.org/10.1016/S0022-1759(03)00265-5; PMID: 14580882
   PubMed Web of Science ®Google Scholar